Profound increases private placement to $6.45M (U.S.)

Mr. Stephen Kilmer reports PROFOUND MEDICAL CORP. ANNOUNCES UPSIZE OF PRIVATE PLACEMENT Profound Medical Corp. has increased the size of its private placement previously announced on Dec. 19, 2025, to accommodate participation by a long-term existing investor. The company will raise gross proceeds of up to $6.45-million (U.S.) in the offering, through the issuance of up to 921,428 common shares at a price of $7 (U.S.) per common share. The common shares sold pursuant to the offering will be subject to a hold period of four months plus one day from the closing date of the offering. The closing of the offering is expected to occur on or prior to Dec. 30, 2025. The company intends to use the net proceeds from the offering for expansion of its sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes. About Profound Medical Corp. Profound is a commercial-stage medical device company that develops and markets artificial-intelligence-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The Tulsa procedure, performed using the Tulsa-Pro system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum, ranging from low-, intermediate- or high-risk prostate cancer to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia to men with BPH only and, also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The Tulsa procedure employs real-time MR guidance for precision to preserve patients' urinary continence and sexual function while killing the targeted prostate tissue through precise sound absorption technology that gently heats it to 55 to 57 C. Tulsa is an incision- and radiation-free one-and-done procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively and efficiently treated with Tulsa. There is no bleeding associated with the procedure, no hospital stay is required and most Tulsa patients report quick recovery to their normal routine. Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration. Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumours and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy. We seek Safe Harbor.